Grants alone won’t build a health innovation economy
The Medical Research Future Fund can move money, but without matched capital and demand signals it will not build the companies Australia needs.
Australia produces world-class biomedical science. It then watches the resulting intellectual property be licensed offshore, developed overseas and sold back to its own hospitals at import prices. The pattern is decades old and remarkably stable.
The Strategic Examination of Research and Development (SERD), released on 17 March, says this plainly. Its proposed National Strategic Initiatives are designed to drive startup creation, run proof-of-concept programs, build accelerator pathways and require at least 50% cash co-investment from private and institutional partners.
The instinct is exactly right. Public money should not be expected to do the whole job. It should be used to drag private capital onto the field earlier, more forcefully and more deliberately.
But the SERD panel also warned explicitly against partial adoption, arguing its recommendations are mutually reinforcing and that incremental selection would deliver another round of band-aid solutions. Australia has a long history of filing well-made reviews politely beside the last one. The question is whether the 12 May Budget turns SERD’s architecture into fiscal commitments, or cherry-picks the cheap pieces and defers the rest.
